THERA4CARE

APRE Info Day

Ben Newton, Salvatore Annunziata
Industrial & Scientific Coordinators

Saverio Gravina, Rachele Brancaleoni, Laura Motta
WP1 Core Group FPG-Unicatt

Kostantinos Zormpas Petridis, Maria R. Ruggiero, Anita Florit, Daniele A. Pizzuto, Chiara Franciosi
WP2,3,5,6,9 FPG-Unicatt & Medipass

Rome, Italy

Project Figures



innovative health initiative

Co-funded by the European Union

1° Oct 2025-2029

THERA4CARE

The largest EU Consortium on Theranostics

Partners

Università Cattolica del Sacro Cuore

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Università Cattolica del Sacro Cuore

SaludMadrid
Hospital Universitario Gregorio Marañón

European Association of Nuclear Medicine

ico

Paul Scherrer Institut PSI

Universitätsklinikum Essen

Erasmus MC
Universitair Medisch Centrum Rotterdam

Oncidium foundation

University of Gothenburg

sckcen

Institut Jules Bordet

Datawizard

collaborate
Project Management

syreon
Research Institute

In-Kind Contributing Partners

GE HealthCare

TERTHERA
Terbium Theranostics

ATLEY
Solutions

curasight

minerva
IMAGING

DOSIsoft

aiforia

EXINI
a LANTHEUS company

PERSPECTIVE THERAPEUTICS

Scientific Background: current challenges In Europe

Limited Radionuclides and Imaging Technology

Insufficient effective radionuclides, especially alpha emitters, and inadequate imaging technology restrict treatment options and monitoring.

Slow Approval Process and Lack of Guidelines

Lengthy approvals and the absence of standardised guidelines, especially for personalised dosimetry, slow clinical adoption and disrupt consistent care.

Production and Facility Limitations

There are few production sites with restricted capabilities. Establishing new facilities is complex, and waste from production is difficult to manage.

Insufficient Predictive Tools and Treatment Centers

A shortage of predictive tools and specialised centres capable of treating large numbers of patients limits treatment response and reach of theranostics.

External Supply Dependence

Reliance on non-EU partners for raw materials and enriched targets introduces supply chain risks and limits self-sufficiency.

Methodology



Rome, Gemelli-Unicatt, 7-8 October 2024

THERA4CARE

Thera4Care is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101172788. The JU receives support from the European Union's Horizon Europe research and innovation programme and COCIR, EFPIA, EuropaBio, MedTech Europe, Vaccines Europe, Atley Solutions, Curasight, Dosisoft, Minerva Imaging, Perspective Therapeutics, and Terthera.

Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the aforementioned parties. Neither of the aforementioned parties can be held responsible for them.

thera4care.eu

info@thera4care.eu

@thera4care